ArticleCureus2024

Beyond the Benefits: A Case Study on the Complications of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (Euglycemic Diabetic Ketoacidosis (DKA) and Takotsubo Cardiomyopathy).

Rand Sabanci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.